Osteoporosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
* All patients who are receiving pharmacologic treatment for osteoporosis, should also undergo lifestyle modifications and supplementation to also prevent further bone loss. | * All patients who are receiving pharmacologic treatment for osteoporosis, should also undergo lifestyle modifications and supplementation to also prevent further bone loss. | ||
* Bisphosphonates - these are potent agents which inhibit resorption of bone<ref name="pmid22805729">{{cite journal |author=Zhang J, Wang R, Zhao YL, ''et al.'' |title=Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis |journal=Asian Pac J Trop Med |volume=5 |issue=9 |pages=743–8 |year=2012 |month=September |pmid=22805729 |doi=10.1016/S1995-7645(12)60118-7 |url=}}</ref>. In turn they increase bone mineral density and decrease the risk of fractures. They include drugs called alendronate, risendronate, ibandronate, and zoledronic acid. | * [[Bisphosphonates]] - these are potent agents which inhibit resorption of bone<ref name="pmid22805729">{{cite journal |author=Zhang J, Wang R, Zhao YL, ''et al.'' |title=Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis |journal=Asian Pac J Trop Med |volume=5 |issue=9 |pages=743–8 |year=2012 |month=September |pmid=22805729 |doi=10.1016/S1995-7645(12)60118-7 |url=}}</ref>. In turn they increase bone mineral density and decrease the risk of fractures. They include drugs called alendronate, risendronate, ibandronate, and zoledronic acid. | ||
* Selective Estrogen Receptor Modulators - otherwise known as SERM's, are approved for the prevention of post-menopausal osteoporosis. They have been shown to increase bone mineral density and decrease the risk of vertebral fractures. Raloxifene <ref name="pmid22405286">{{cite journal |author=Dadiboyena S |title=Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator |journal=Eur J Med Chem |volume=51 |issue= |pages=17–34 |year=2012 |month=May |pmid=22405286 |doi=10.1016/j.ejmech.2012.02.021 |url=}}</ref> is the only SERM approved for use in the United States. | * [[Selective Estrogen Receptor Modulators]] - otherwise known as SERM's, are approved for the prevention of post-menopausal osteoporosis. They have been shown to increase bone mineral density and decrease the risk of vertebral fractures. Raloxifene <ref name="pmid22405286">{{cite journal |author=Dadiboyena S |title=Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator |journal=Eur J Med Chem |volume=51 |issue= |pages=17–34 |year=2012 |month=May |pmid=22405286 |doi=10.1016/j.ejmech.2012.02.021 |url=}}</ref> is the only SERM approved for use in the United States. | ||
* Estrogen - with or without medroxyprogesterone can be used to prevent osteoporosis, however in general the risks outweigh the benefits, so it is not used as a first-line therapy. It is used in women who have a significant risk of osteoporotic fractures and cannot take non-estrogen medications. | * [[Estrogen]] - with or without medroxyprogesterone can be used to prevent osteoporosis, however in general the risks outweigh the benefits, so it is not used as a first-line therapy. It is used in women who have a significant risk of osteoporotic fractures and cannot take non-estrogen medications. | ||
==References== | ==References== | ||
Revision as of 19:22, 30 July 2012
|
Osteoporosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Osteoporosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Osteoporosis secondary prevention |
|
Risk calculators and risk factors for Osteoporosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Raviteja Guddeti, M.B.B.S.[3]
Overview
Secondary prevention involves use of medications, based on the earliest possible identification of disease so that it can be more readily treated or managed and adverse sequelae can be prevented.
Secondary prevention
Pharmacologic Therapy
- All patients who are receiving pharmacologic treatment for osteoporosis, should also undergo lifestyle modifications and supplementation to also prevent further bone loss.
- Bisphosphonates - these are potent agents which inhibit resorption of bone[1]. In turn they increase bone mineral density and decrease the risk of fractures. They include drugs called alendronate, risendronate, ibandronate, and zoledronic acid.
- Selective Estrogen Receptor Modulators - otherwise known as SERM's, are approved for the prevention of post-menopausal osteoporosis. They have been shown to increase bone mineral density and decrease the risk of vertebral fractures. Raloxifene [2] is the only SERM approved for use in the United States.
- Estrogen - with or without medroxyprogesterone can be used to prevent osteoporosis, however in general the risks outweigh the benefits, so it is not used as a first-line therapy. It is used in women who have a significant risk of osteoporotic fractures and cannot take non-estrogen medications.
References
- ↑ Zhang J, Wang R, Zhao YL; et al. (2012). "Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta-analysis". Asian Pac J Trop Med. 5 (9): 743–8. doi:10.1016/S1995-7645(12)60118-7. PMID 22805729. Unknown parameter
|month=ignored (help) - ↑ Dadiboyena S (2012). "Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator". Eur J Med Chem. 51: 17–34. doi:10.1016/j.ejmech.2012.02.021. PMID 22405286. Unknown parameter
|month=ignored (help)